Evidence map›Paper›PMID 21932384›Full record

ArticleHepatology (Baltimore, Md.)2012

Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population.

Hiroyoshi Doi, Tara K Iyer, Erica Carpenter, Hong Li, Kyong-Mi Chang, Robert H Vonderheide, David E Kaplan

Registry-linked trialAbstract readComparative Study
In one paragraph

Article in Hepatology (Baltimore, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01951209 (Prospective Pilot Study of the Effect of Rifaximin on B-Cell Dysregulation in Cirrhosis Due to Chronic Hepatitis C Infection), which is not on this map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01951209 naterminatednot on this mapstarted 2016, after this paper: background citation

Prospective Pilot Study of the Effect of Rifaximin on B-Cell Dysregulation in Cirrhosis Due to Chronic Hepatitis C Infection

TypeinterventionalSponsorDavid E. Kaplan, MD MScRan2016 to 2017Enrolled13ConditionsLiver Cirrhosis, Chronic Hepatitis CArmsRifaximin, Placebo
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Liver Cirrhosis: The Immunocompromised State.Journal of clinical medicine · 2024
    Review
  8. Article
  9. Review
  10. Comparison of fungalWorld journal of hepatology · 2024
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Liver cirrhosis and immune dysfunction.International immunology · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hiroyoshi DoiDivision of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Tara K Iyer
Erica Carpenter
Hong Li
Kyong-Mi Chang
Robert H Vonderheide
David E Kaplan
University of Pennsylvania · USCancer Research Institute · USVeterans Health Administration · US

Funding

TRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Ken Hashigiwa Cadwell · 1997 to 2026
$32.5M
CELLULAR IMMUNITY--OUTCOME HEPATITIS C VIRUS INFECTIONR01AI047519 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CHANG, KYONG-MI · 1999 to 2010
$3.1M
ALCOHOL/CELLULAR IMMUNITY IN HCV AND HIV INFECTIONR01AA012849 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI CHANG, KYONG-MI · 2000 to 2004
$1.9M
Engineered lymphocytes for the treatment of hepatocellular carcinomaR21CA149908 · NCI · UNIVERSITY OF PENNSYLVANIA · PI KAPLAN, DAVID E · 2010 to 2011
$296k
NCI NIH HHS R21 CA149908NIAAA NIH HHS AA12849NIAAA NIH HHS R01 AA012849NIAID NIH HHS AI47519NIAID NIH HHS R01 AI047519NIDDK NIH HHS L30 DK069063NIDDK NIH HHS P30 DK050306NIDDK NIH HHS P30-DK050306
6 · The paper itself

Abstract

unlabelledChronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis and hepatocellular carcinoma (HCC). Both advanced solid tumors and HCV have previously been associated with memory B-cell dysfunction. In this study, we sought to dissect the effect of viral infection, cirrhosis, and liver cancer on memory B-cell frequency and function in the spectrum of HCV disease. Peripheral blood from healthy donors, HCV-infected patients with F1-F2 liver fibrosis, HCV-infected patients with cirrhosis, patients with HCV-related HCC, and non-HCV-infected cirrhotics were assessed for B-cell phenotype by flow cytometry. Isolated B cells were stimulated with anti-cluster of differentiation (CD)40 antibodies and Toll-like receptor (TLR)9 agonist for assessment of costimulation marker expression, cytokine production, immunoglobulin (Ig) production, and CD4(+) T-cell allostimulatory capacity. CD27(+) memory B cells and, more specifically, CD27(+) IgM(+) B cells were markedly less frequent in cirrhotic patients independent of HCV infection. Circulating B cells in cirrhotics were hyporesponsive to CD40/TLR9 activation, as characterized by CD70 up-regulation, tumor necrosis factor beta secretion, IgG production, and T-cell allostimulation. Last, blockade of TLR4 and TLR9 signaling abrogated the activation of healthy donor B cells by cirrhotic plasma, suggesting a role for bacterial translocation in driving B-cell changes in cirrhosis.

conclusionProfound abnormalities in B-cell phenotype and function occur in cirrhosis independent of HCV infection. These B-cell defects may explain, in part, the vaccine hyporesponsiveness and susceptibility to bacterial infection in this population.

Indexed as

PhenotypeB-LymphocytesCarcinoma, HepatocellularCase-Control StudiesCD27 LigandCD40 AntigensCells, CulturedCytokinesFemaleHepatitis CHumansImmunoglobulin GLiver CirrhosisLiver NeoplasmsMaleMiddle AgedCD27 LigandCD40 AntigensCytokinesImmunoglobulin GToll-Like Receptor 4Toll-Like Receptor 9Tumor Necrosis Factor Receptor Superfamily, Member 7

Identifiers

PMID21932384
PMCPMC3245804
OpenAlexW2075220070

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.